Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection

A Hata, N Katakami, H Yoshioka, S Fujita, K Kunimasa… - Lung cancer, 2011 - Elsevier
BACKGROUND: Recent reports have suggested that erlotinib therapy after gefitinib failure
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …
被引用次数：86 相关文章

[引用][C] Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection

A HATA, N KATAKAMI, A NISHIYAMA… - Lung …, 2011 - pascal-francis.inist.fr
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with
optimal patient selection CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection

A Hata, N Katakami, H Yoshioka… - Lung cancer …, 2011 - pubmed.ncbi.nlm.nih.gov
Background Recent reports have suggested that erlotinib therapy after gefitinib failure
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection

A Hata, N Katakami, H Yoshioka, S Fujita… - Lung …, 2011 - lungcancerjournal.info
Background Recent reports have suggested that erlotinib therapy after gefitinib failure
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection

A Hata, N Katakami, H Yoshioka, S Fujita, K Kunimasa… - Lung Cancer, 2011 - infona.pl
Recent reports have suggested that erlotinib therapy after gefitinib failure requires optimal
patient selection to obtain clinical benefits in relapsed non-small cell lung cancer (NSCLC) …

[引用][C] Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection

A Hata, N Katakami, H Yoshioka, S Fujita, K Kunimasa… - Lung Cancer, 2011 - cir.nii.ac.jp
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with
optimal patient selection | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.

A Hata, N Katakami, H Yoshioka, S Fujita… - Lung Cancer …, 2011 - europepmc.org
Background Recent reports have suggested that erlotinib therapy after gefitinib failure
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …

[引用][C] Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection

A HATA - Lung Cancer, 2011 - cir.nii.ac.jp